Brazil Cardiovascular Drugs Market Analysis Report 2022 to 2030

Brazil Cardiovascular Drugs Market Analysis

$ 3999

Brazil Cardiovascular Drug Market is at around $3.5 Bn in 2022 and is projected to reach $5.03 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. Primary factors driving the expansion of this industry include government initiatives, increasing prevalence of cardiovascular diseases, and an aging population. The market is dominated by key players like Eurofarma, Nortec Química (BRA), Drogaria do Povo (BR), Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, and Merck & Co., Inc.

ID: IN10BRPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Aneri Parekh

Buy Now

Brazil Cardiovascular Drug Market Executive Summary

Brazil Cardiovascular Drug Market is at around $3.5 Bn in 2022 and is projected to reach $5.03 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period.

Cardiovascular diseases (CVDs) are disorders of the heart and blood vessels. These constitute deep vein thrombosis, pulmonary embolism, congenital heart disease, peripheral artery disease, rheumatic heart disease, and coronary heart disease. Angiotensin-II antagonists (like losartan), antiarrhythmics (like amiodarone), and ACE inhibitors (like ramipril) are the three main classes of medications used to treat heart-related issues.

Given the rising prevalence of cardiovascular diseases with a rise of 26.8% in the past three decades, rising public awareness, expanding access to healthcare, and developments in technology, the Brazilian market for cardiovascular medications is well-positioned for future growth. While pricing pressure is still a problem, there is new potential in generics and innovative medicines, so the overall picture is favorable.

Pharmaceutical revenue increased significantly over the preceding two decades, reaching $138.33 Bn globally in 2022. With the introduction of new technologies and more economical and effective manufacturing techniques, the pharmaceutical industry has undergone a significant transformation. Moreover, this industry's growing capital inflow has contributed to the market's expansion.

Brazilian pharmaceutical giant Eurofarma intends to invest up to $100 Mn in biotech businesses that are just starting in the early phases of drug research and development. Eurofarma regularly interacts with research universities and other pharmaceutical businesses to speed cardiovascular care developments. To increase awareness and facilitate better access to necessary pharmaceuticals, they also collaborate with healthcare institutions.

Brazil cardiovascular drug market

Market Dynamics

Market Growth Drivers:

Government Initiatives: The market for cardiovascular medications benefits from government initiatives aimed at lowering the prevalence of cardiovascular diseases, enhancing healthcare infrastructure, and encouraging preventative measures. The Brazilian government invested around $27.2 Bn in healthcare in 2022.

Cardiovascular Disease Prevalence: Cardiovascular medications are going in high demand due to the high incidence and prevalence of cardiovascular disorders in Brazil.

Increasing Population Age: Brazil's aging population may result in a higher burden of cardiovascular illnesses since these conditions are more prevalent in the elderly. There may be a greater need for cardiovascular medications due to the aging population. The number of individuals 65 and older increased by 57% between 2010 and 2022, from 14.1 Mn to 22.2 Mn, making up 11% of the population.

Market Restraints:

Competition from Non-pharmacological Therapies: When it comes to treating cardiovascular diseases, non-pharmacological therapies including dietary adjustments, lifestyle changes, and medical gadgets may pose a threat to pharmaceutical treatments.

Research & Development Expenses: Substantial expenses linked to the investigation and creation of novel cardiovascular medications may result in elevated pricing for these pharmaceuticals, hence restricting their widespread usage.

Pricing Pressures: Pharmaceutical companies may face pressure to lower the cost of cardiovascular medications, which could affect their revenue streams, through price discussions with government agencies, insurers, and healthcare payers.

Healthcare Policies and Regulatory Landscape

Brazilian Health Regulatory Agency (ANVISA), an autarchy under the Ministry of Health, is responsible for coordinating the Brazilian Health Regulatory System (SNVS), which is implemented over the entire country. It is a component of the Brazilian National Health System (SUS). ANVISA approval is required for product registration in Brazil. The product dossier must be submitted in eCTD format. Novel medications have to prove their safety and efficacy through a variety of non-clinical and clinical studies.

Competitive Landscape

Key Players:

Eurofarma
Nortec Química (BRA)
Drogaria do Povo (BR)
Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
AstraZeneca
Sanofi
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Brazil Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Other

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.